Is BPC 157 Banned? Oral vs. Injectable Forms Explained The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide The Human Lab Rats Injecting Themselves with Peptides Office for Science and Society McGill University BPC 157: Miracle Healing Peptide or Hidden Danger? NDI warning letters fuel criticism of FDA enforcement approach BPC 157 500 mcg Oral Capsules